Testing Vitamin D Analogues for Vascular Calcification in Patients With CKD

Affiliations

Editorial

Madhuri Ramakrishnan et al. Kidney Med. 2020.

. 2020 Jul 2;2(4):385-387.

doi: 10.1016/j.xkme.2020.06.003. eCollection 2020 Jul-Aug.

¹ Division of Nephrology, Department of Medicine, Washington University, St. Louis, MO.

No abstract available

Comment on

Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol.
Anis KH, Pober D, Rosas SE. Anis KH, et al. Kidney Med. 2020 Jun 17;2(4):450-458. doi: 10.1016/j.xkme.2020.05.009. eCollection 2020 Jul-Aug. Kidney Med. 2020. PMID: 32775985 Free PMC article.

1. Nordal K.P., Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988;67:929–936. - PubMed
1. Coburn J.W., Maung H.M., Elangovan L. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis. 2004;43:877–890. - PubMed
1. Coyne D., Acharya M., Qiu P. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47:263–276. - PubMed
1. Wolf M., Shah A., Gutierrez O. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004–1013. - PubMed
1. Bhan I., Thadhani R. Vitamin D. Academic Press; London, UK: 2018. Calcitriol and analogs in the treatment of chronic kidney disease; pp. 471–484.